Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.11 +5.3%	$1.58	$0.87 ▼ $6.37	$212.14M	0.86	809,112 shs	128,120 shs
AVTE Aerovate Therapeutics	$7.40 -1.2%	$8.64	$56.35 ▼ $105.00	$214.49M	0.95	12,438 shs	69,957 shs
CGTX Cognition Therapeutics	$1.36 +23.2%	$0.52	$0.22 ▼ $1.47	$95.95M	1	4.17 million shs	25.23 million shs
CRGX CARGO Therapeutics	$4.46 -0.1%	$4.45	$3.00 ▼ $25.45	$215.44M	0.3	1.19 million shs	89,873 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	-10.31%	+28.21%	+24.22%	+86.92%	-60.82%
AVTE Aerovate Therapeutics	-1.20%	+7.40%	-24.64%	-14.05%	-87.71%
CGTX Cognition Therapeutics	+28.10%	+53.63%	+93.87%	+229.84%	+93.46%
CRGX CARGO Therapeutics	-0.45%	0.00%	-2.83%	+16.15%	-69.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALEC Alector	4.0936 of 5 stars	3.1	3.0	0.0	4.5	3.0	2.5	0.0
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	2.7593 of 5 stars	3.6	2.0	0.0	0.0	3.3	1.7	0.6
CRGX CARGO Therapeutics	2.3012 of 5 stars	2.9	0.0	0.0	0.0	2.8	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.29	Hold	$4.17	97.94% Upside
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
CGTX Cognition Therapeutics	3.25	Buy	$2.83	109.10% Upside
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	245.68% Upside

Current Analyst Ratings Breakdown

Latest CGTX, ALEC, CRGX, and AVTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
7/28/2025	ALEC Alector	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$2.50 ➝ $3.50
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00
6/26/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$100.56M	2.12	N/A	N/A	$0.70 per share	3.01
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.10 per share	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$4.91 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$119.05M	-$1.16	N/A	N/A	N/A	-142.10%	-112.06%	-26.37%	N/A
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
CGTX Cognition Therapeutics	-$33.97M	-$0.67	N/A	N/A	N/A	N/A	-251.23%	-130.75%	8/14/2025 (Estimated)
CRGX CARGO Therapeutics	-$167.50M	-$4.64	N/A	N/A	N/A	N/A	-43.21%	-37.26%	N/A

Latest CGTX, ALEC, CRGX, and AVTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	ALEC Alector	-$0.45	-$0.30	+$0.15	-$0.30	$2.76 million	$7.87 million
8/7/2025	Q2 2025	CGTX Cognition Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.13	3.78	3.78
AVTE Aerovate Therapeutics	N/A	8.78	8.78
CGTX Cognition Therapeutics	N/A	1.54	1.54
CRGX CARGO Therapeutics	N/A	12.37	12.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
AVTE Aerovate Therapeutics	N/A
CGTX Cognition Therapeutics	43.35%
CRGX CARGO Therapeutics	93.16%

Insider Ownership

Company	Insider Ownership
ALEC Alector	9.70%
AVTE Aerovate Therapeutics	24.90%
CGTX Cognition Therapeutics	14.40%
CRGX CARGO Therapeutics	2.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	101.21 million	91.39 million	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
CGTX Cognition Therapeutics	20	73.47 million	62.89 million	Not Optionable
CRGX CARGO Therapeutics	116	48.36 million	46.95 million	N/A

CGTX, ALEC, CRGX, and AVTE Headlines

Recent News About These Companies

Reviewing CARGO Therapeutics (NASDAQ:CRGX) & Pliant Therapeutics (NASDAQ:PLRX)

August 13 at 2:17 AM | americanbankingnews.com

CARGO Therapeutics, Inc. (NASDAQ:CRGX) Given Average Recommendation of "Reduce" by Analysts

August 7, 2025 | americanbankingnews.com

CARGO Therapeutics (CRGX) Expected to Announce Earnings on Monday

August 5, 2025 | marketbeat.com

Alberta Investment Management Corp Takes $380,000 Position in CARGO Therapeutics, Inc. (NASDAQ:CRGX)

August 5, 2025 | marketbeat.com

TD Asset Management Inc Decreases Holdings in CARGO Therapeutics, Inc. (NASDAQ:CRGX)

August 5, 2025 | marketbeat.com

CARGO Therapeutics, Inc. (NASDAQ:CRGX) Given Average Rating of "Reduce" by Brokerages

August 3, 2025 | marketbeat.com

Monaco Asset Management SAM Buys Shares of 139,028 CARGO Therapeutics, Inc. (NASDAQ:CRGX)

July 31, 2025 | marketbeat.com

Jefferies Raises Price Target for Cargo Therapeutics (CRGX), Keeps Hold Rating

July 29, 2025 | msn.com

CARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CARGO Therapeutics, Inc. - CRGX

July 25, 2025 | businesswire.com

URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger - CRGX, HSON, BRZH, and ENZB

July 25, 2025 | prnewswire.com

CRGX - Cargo Therapeutics Inc Financials | Morningstar

July 19, 2025 | morningstar.comM

CARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of ...

July 11, 2025 | morningstar.comM

Concentra Biosciences Set to Acquire CAR T-Cell Innovator CARGO Therapeutics in Cash Deal

July 10, 2025 | hoodline.comH

CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right - Seeking Alpha

July 9, 2025 | seekingalpha.com

CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right - Morningstar

July 9, 2025 | morningstar.comM

CARGO Therapeutics to be acquired by Concentra Biosciences in $4.379 a - Seeking Alpha

July 9, 2025 | seekingalpha.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CARGO Therapeutics, Inc. (NASDAQ: CRGX)

July 9, 2025 | globenewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRGX and WNS on Behalf of Shareholders

July 9, 2025 | globenewswire.com

Concentra extends biotech shopping spree by collecting Cargo

July 8, 2025 | fiercebiotech.comF

Tang Capital makes bid for 4th Bay Area biotech in 3 months, offering to take out Cargo Therapeutics

July 8, 2025 | bizjournals.com

Concentra adds CARGO Therapeutics to its biotech buy haul

July 8, 2025 | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX, ALEC, CRGX, and AVTE Company Descriptions

Alector NASDAQ:ALEC

$2.10 +0.11 (+5.25%)

As of 10:10 AM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Aerovate Therapeutics NASDAQ:AVTE

$7.40 -0.09 (-1.20%)

As of 08/11/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Cognition Therapeutics NASDAQ:CGTX

$1.36 +0.26 (+23.18%)

As of 10:10 AM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

CARGO Therapeutics NASDAQ:CRGX

$4.46 -0.01 (-0.11%)

As of 10:09 AM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time